$BTAI
BioXcel Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023008597 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $457.0K $206.0K
YoY Change
Cost Of Revenue $26.00K $9.000K
YoY Change
Gross Profit $431.0K $197.0K
YoY Change
Gross Profit Margin 94.31% 95.63%
Selling, General & Admin $25.87M $23.60M
YoY Change 40.75% 82.61%
% of Gross Profit 6002.78% 11977.16%
Research & Development $26.97M $27.80M
YoY Change 50.64% 49.79%
% of Gross Profit 6258.24% 14111.68%
Depreciation & Amortization $81.00K $80.00K
YoY Change -3.57% 3.9%
% of Gross Profit 18.79% 40.61%
Operating Expenses $52.85M $51.40M
YoY Change 45.63% 63.26%
Operating Profit -$52.41M -$51.20M
YoY Change 44.44% 62.64%
Interest Expense $3.259M $3.367M
YoY Change 105.49% 48000.0%
% of Operating Profit
Other Income/Expense, Net $537.0K -$246.0K
YoY Change
Pretax Income -$53.52M -$52.80M
YoY Change 42.06% 67.76%
Income Tax
% Of Pretax Income
Net Earnings -$53.52M -$52.80M
YoY Change 42.06% 67.76%
Net Earnings / Revenue -11710.07% -25629.13%
Basic Earnings Per Share -$1.83 -$1.84
Diluted Earnings Per Share -$1.83 -$1.84
COMMON SHARES
Basic Shares Outstanding 29.16M 29.01M
Diluted Shares Outstanding 29.19M 28.62K

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $127.5M $165.5M
YoY Change -45.37% -17.42%
Cash & Equivalents $127.5M $165.5M
Short-Term Investments
Other Short-Term Assets $4.636M $5.006M
YoY Change 173.83% 238.7%
Inventory $1.925M $1.952M
Prepaid Expenses
Receivables $431.0K $283.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $138.2M $177.3M
YoY Change -43.56% -14.6%
LONG-TERM ASSETS
Property, Plant & Equipment $941.0K $1.004M
YoY Change -26.02% -24.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $87.00K $925.0K
YoY Change -90.59% -4.15%
Total Long-Term Assets $1.862M $2.835M
YoY Change -43.76% -18.6%
TOTAL ASSETS
Total Short-Term Assets $138.2M $177.3M
Total Long-Term Assets $1.862M $2.835M
Total Assets $140.1M $180.1M
YoY Change -43.56% -14.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.20M $7.742M
YoY Change 86.07% 52.85%
Accrued Expenses $19.13M $17.07M
YoY Change 43.05% 61.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.74M $28.76M
YoY Change 73.76% 79.78%
LONG-TERM LIABILITIES
Long-Term Debt $96.85M $95.06M
YoY Change 58.57%
Other Long-Term Liabilities $2.643M $3.277M
YoY Change -8.96% 218.77%
Total Long-Term Liabilities $96.85M $95.06M
YoY Change 58.57% 9147.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.74M $28.76M
Total Long-Term Liabilities $96.85M $95.06M
Total Liabilities $134.2M $127.1M
YoY Change 59.85% 646.54%
SHAREHOLDERS EQUITY
Retained Earnings -$517.9M -$464.3M
YoY Change 64.44% 67.47%
Common Stock $29.00K $29.00K
YoY Change 3.57% 3.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.864M $53.01M
YoY Change
Total Liabilities & Shareholders Equity $140.1M $180.1M
YoY Change -43.56% -14.66%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$53.52M -$52.80M
YoY Change 42.06% 67.76%
Depreciation, Depletion And Amortization $81.00K $80.00K
YoY Change -3.57% 3.9%
Cash From Operating Activities -$38.21M -$52.35M
YoY Change 15.42% 61.52%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $0.00
YoY Change -205.26% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K $0.00
YoY Change 5.26% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K 24.15M
YoY Change -99.62%
NET CHANGE
Cash From Operating Activities -38.21M -52.35M
Cash From Investing Activities -20.00K 0.000
Cash From Financing Activities 250.0K 24.15M
Net Change In Cash -37.98M -28.20M
YoY Change -215.02% -13.31%
FREE CASH FLOW
Cash From Operating Activities -$38.21M -$52.35M
Capital Expenditures $20.00K $0.00
Free Cash Flow -$38.23M -$52.35M
YoY Change 15.54% 60.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001720893
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29100000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28147000
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38410
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BioXcel Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1386754
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
555 Long Wharf Drive
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New Haven
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06511
CY2023Q1 dei City Area Code
CityAreaCode
475
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
238-6837
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
BTAI
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29159638
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165521000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193725000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
283000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
248000
CY2023Q1 us-gaap Inventory Net
InventoryNet
1952000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1985000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4506000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3067000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
5006000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3843000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
177268000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
202868000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1004000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1084000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
906000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
976000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
925000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
925000
CY2023Q1 us-gaap Assets
Assets
180103000
CY2022Q4 us-gaap Assets
Assets
205853000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7742000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10228000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17065000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18669000
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
380000
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
422000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3088000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3175000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
484000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
404000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
28759000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32898000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
703000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
786000
CY2023Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2574000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2343000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
95062000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
93051000
CY2023Q1 us-gaap Liabilities
Liabilities
127098000
CY2022Q4 us-gaap Liabilities
Liabilities
129078000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29100000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28147000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
29000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
517317000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
488292000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-464341000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-411545000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
53005000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76775000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180103000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
205853000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
206000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27800000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18559000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23595000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12921000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
51404000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
31480000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-51198000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-31480000
CY2023Q1 us-gaap Interest Expense
InterestExpense
3367000
CY2022Q1 us-gaap Interest Expense
InterestExpense
7000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2015000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
15000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-246000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31472000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28616000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27980000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
221667000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3825000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31472000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
194020000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76775000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23918000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4877000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
258000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-27000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
53005000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-52796000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-31472000
CY2023Q1 us-gaap Depreciation
Depreciation
80000
CY2022Q1 us-gaap Depreciation
Depreciation
77000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
333000
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-231000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4877000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3825000
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
398000
CY2023Q1 btai Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-70000
CY2022Q1 btai Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-66000
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
35000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-33000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
682000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2006000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3480000
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4654000
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-676000
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1193000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-77000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-71000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52353000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32413000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
120000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-120000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24657000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
739000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
27000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
258000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24149000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28204000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32533000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193725000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
232968000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165521000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200435000
CY2023Q1 btai Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
596000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (“BTI” or the “Company”) is a biopharmaceutical company utilizing artificial intelligence (“AI”) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BTI employs a unique AI platform designed to reduce therapeutic development costs and potentially accelerate timelines. The Company’s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these condensed consolidated financial statements, unless otherwise specified or the context otherwise requires, the term “BioXcel LLC” refers to the Company’s former parent and current significant stockholder and its predecessor, BioXcel Corporation. “OnkosXcel” refers to BTI’s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the U.S. FDA approved IGALMI (dexmedetomidine or “Dex”) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI is approved to be self-administrated by patients under the supervision of a healthcare provider. On July 6, 2022, BTI announced that IGALMI, was commercially available in doses of 120 and 180 micrograms through the Company’s third-party logistics provider and was available for order through wholesalers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s most advanced clinical development program is BXCL501, an investigational proprietary, orally dissolving film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI is conducting clinical trials for the at-home use of BXCL501 for agitation associated with bipolar disorders and schizophrenia. The Company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in patients with Alzheimer’s disease in residential care facilities and nursing homes and for adjunctive treatment of patients with Major Depressive Disorder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company’s principal office is in New Haven, Connecticut.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Impact of COVID-19 Pandemic</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The COVID-19 pandemic and responsive measures have significantly impacted, both directly and indirectly, businesses and commerce.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company continues to work closely with clinical sites to monitor the potential impact of the evolving COVID-19 pandemic and the spread of its variants. To date, BTI has not experienced any significant delays in any of its ongoing or planned clinical trials, except for occasional COVID-19 related disruptions, such as to its TRANQUILITY II trial. However, this could change rapidly.</p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165521000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-464341000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31472000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52353000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32413000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and notes thereto. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The Company sells IGALMI through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (“GPOs”). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span></p>
CY2023Q1 us-gaap Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure
RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s revenues consist of product sales of IGALMI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company’s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company’s behalf. The Company believes the hospitals are its customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its condensed consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer’s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company’s only performance obligation identified for IGALMI is to deliver the quantity of product ordered to the location specified by the customer’s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Condensed Consolidated Statements of Operations. Under the Company’s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI at wholesale acquisition cost and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">IGALMI is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Condensed Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI’s Condensed Consolidated Statements of Operations.</p>
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
682000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
682000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
708000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1270000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
595000
CY2023Q1 us-gaap Inventory Net
InventoryNet
1952000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1985000
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1969000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1969000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
965000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
885000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1004000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1084000
CY2023Q1 us-gaap Depreciation
Depreciation
80000
CY2022Q1 us-gaap Depreciation
Depreciation
77000
CY2023Q1 btai Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
10254000
CY2022Q4 btai Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
8659000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2654000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6370000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3735000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2738000
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
212000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
82000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
210000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
820000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17065000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18669000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
103115000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
101437000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
8053000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
8386000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
95062000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
93051000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1254000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10479000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
86094000
CY2023Q1 btai Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
5288000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
3034000
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
7000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
333000
CY2023Q1 us-gaap Interest Expense
InterestExpense
3367000
CY2022Q1 us-gaap Interest Expense
InterestExpense
7000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4877000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3825000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4877000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3825000
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
280000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
381000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
391000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
65000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1117000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
89000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1028000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
325000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
703000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
325000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
99000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
98000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2343000
CY2023Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
231000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2574000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31472000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28616
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27980
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5868000
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4782000
CY2022Q2 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
10000000
CY2022Q2 btai Agreement Commitment Period
AgreementCommitmentPeriod
P3Y

Files In Submission

Name View Source Status
btai-20230331_pre.xml Edgar Link unprocessable
0001558370-23-008597-index-headers.html Edgar Link pending
0001558370-23-008597-index.html Edgar Link pending
0001558370-23-008597.txt Edgar Link pending
0001558370-23-008597-xbrl.zip Edgar Link pending
btai-20230331.xsd Edgar Link pending
btai-20230331x10q.htm Edgar Link pending
btai-20230331x10q006.jpg Edgar Link pending
btai-20230331x10q007.jpg Edgar Link pending
btai-20230331xex10d1.htm Edgar Link pending
btai-20230331xex10d2.htm Edgar Link pending
btai-20230331xex10d3.htm Edgar Link pending
btai-20230331xex31d1.htm Edgar Link pending
btai-20230331xex31d2.htm Edgar Link pending
btai-20230331xex32d1.htm Edgar Link pending
btai-20230331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
btai-20230331_cal.xml Edgar Link unprocessable
btai-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
btai-20230331_lab.xml Edgar Link unprocessable
btai-20230331x10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending